BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $749,251 | +157.8% | 28,413 | -25.5% | 0.03% | +64.7% |
| Q4 2022 | $290,596 | +56.2% | 38,136 | +103.8% | 0.02% | +41.7% |
| Q3 2022 | $186,000 | -72.5% | 18,708 | -74.9% | 0.01% | -52.0% |
| Q2 2022 | $676,000 | +327.8% | 74,400 | +378.1% | 0.02% | +316.7% |
| Q1 2022 | $158,000 | -79.7% | 15,560 | -66.7% | 0.01% | -82.9% |
| Q4 2021 | $779,000 | +215.4% | 46,695 | +785.9% | 0.04% | +150.0% |
| Q3 2021 | $247,000 | – | 5,271 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |